Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response-Reference-Cited by-同舟云学术

Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Cao Kankan¹,Zhang Guodong¹,Zhang Xiangyun²,Yang Moran¹,Wang Yiying¹,He Mengdi¹,Lu Jiaqi¹³,Liu Haiou¹^ORCID

Affiliation:

1. Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

2. Department of Gynecology, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China

3. Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Funder

National Natural Science Foundation

Natural Science Foundation of Shanghai

Shanghai Sailing Program

Natural Science Foundation of Xinjiang Uygur Autonomous Region

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1969075

Reference51 articles.

1. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

2. null

3. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

4. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

5. SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Mitochondrial activity related genes of mast cells identify poor prognosis and metastasis of ovarian cancer;Immunobiology;2024-09

3. Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy;Clinical and Translational Medicine;2024-09

4. Advances and challenges in the origin and evolution of ovarian cancer organoids;Frontiers in Oncology;2024-08-16

5. Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper;Allergy;2024-07-22